K. Vaddi

发表

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2010, Blood.

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

J. Fridman, H. Koblish, P. Scherle, 2010, Molecular Cancer Therapeutics.

Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

R. Wynn, A. Margulis, E. Crowgey, 2009, Clinical Cancer Research.

A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease.

J. McPherson, K. Vaddi, B. Friedman, 1999, Blood.

Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans

J. Trzăskos, T. Maduskuie, C. Garner, 2007, Drug Metabolism and Disposition.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, British journal of haematology.

Identification and Characterization of INCB 9471 , an Allosteric Noncompetitive Small-Molecule Antagonist of C-C Chemokine Receptor 5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1 Infection

P. Scherle, N. Zhou, F. Baribaud, 2011 .

Identification and Characterization of INCB9471, an Allosteric Noncompetitive Small-Molecule Antagonist of C-C Chemokine Receptor 5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1 Infection

P. Scherle, N. Zhou, F. Baribaud, 2011, Journal of Pharmacology and Experimental Therapeutics.

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

S. Verstovsek, K. Vaddi, J. Kiladjian, 2016, Blood and lymphatic cancer : targets and therapy.

Selective JAK inhibition proves efficacious in epithelial cancer models

J. Fridman, Jun Li, X. Wen, 2008 .

MIP-2 – Macrophage inflammatory protein-2

K. Vaddi, 1997 .

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

R. Wynn, A. Margulis, H. Koblish, 2018, PloS one.

The chemokine factsbook

K. Vaddi, R. Newton, M. Keller, 1997 .

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.

P. Scherle, K. Vaddi, M. Covington, 2011, ACS medicinal chemistry letters.

PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN.

K. Helin, R. Koche, R. Levine, 2020, Cancer discovery.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

S. Verstovsek, K. Vaddi, N. Sarlis, 2014, International journal of general medicine.

Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach.

R. Wynn, P. Scherle, K. Vaddi, 2022, Bioorganic & medicinal chemistry letters.

Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation.

J. Mehta, K. Vaddi, F. Nicolini, 1994, Circulation.

CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.

I. Kariv, K. Vaddi, M. Covington, 2007, Bioorganic & medicinal chemistry letters.

Transgenic animals in inflammatory disease models.

K. Vaddi, C. Brodmerkel, 2003, Current opinion in biotechnology.

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

D. Steensma, J. Lancet, M. Sekeres, 2016, Clinical Cancer Research.

Selective Inhibition of Eosinophil Influx into the Lung by Small Molecule CC Chemokine Receptor 3 Antagonists in Mouse Models of Allergic Inflammation

K. McIntyre, S. Mandlekar, J. Trzăskos, 2006, Journal of Pharmacology and Experimental Therapeutics.

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

J. Fridman, Jun Li, X. Wen, 2010, The Journal of Immunology.

Selective Inhibition of JAK 1 and JAK 2 Is Efficacious in Rodent Models of Arthritis : Preclinical Characterization of INCB 028050

J. Fridman, Jun Li, X. Wen, 2010 .

Preclinical Characterization of INCB 028050 Efficacious in Rodent Models of Arthritis : Selective Inhibition of JAK 1 and JAK 2 Is

J. Fridman, Jun Li, X. Wen, 2010 .

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

Vikas Gupta, K. Vaddi, N. Sarlis, 2012, Expert opinion on pharmacotherapy.

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

Z. Estrov, H. Kantarjian, J. Cortes, 2011, Cancer.

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

A. Gottlieb, P. Scherle, K. Vaddi, 2015, The British journal of dermatology.

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2011 .

Biological responses to C-C chemokines.

K. Vaddi, R. Newton, 1997, Methods in enzymology.

PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN.

K. Helin, R. Koche, R. Levine, 2019, Cancer discovery.

Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

J. Trzăskos, W. Marshall, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

RANTES – Regulated on activation, normal T cell expressed and secreted

K. Vaddi, 1997 .

MIP-1α – Macrophage inflammatory protein-1α

K. Vaddi, 1997 .

MIG – Monokine induced by interferon gamma

K. Vaddi, R. Newton, M. Keller, 1997 .

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

J. Fridman, P. Scherle, C. Neilan, 2011, The Journal of investigative dermatology.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)

H. Kantarjian, J. Cortes, S. Verstovsek, 2008 .

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Ayalew Tefferi, Z. Estrov, H. Kantarjian, 2010, The New England journal of medicine.

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions

J. Blachly, R. Baiocchi, D. Sampath, 2022, Science advances.

IP-10 – Gamma interferon inducible protein-10

K. Vaddi, 1997 .

MIP-1β – Macrophage inflammatory protein-1β

K. Vaddi, 1997 .

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

M. Cazzola, T. Barbui, H. Kantarjian, 2009 .

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, L. Leffet, 2005, The Journal of Immunology.

NAP-2 – Neutrophil activating protein-2

K. Vaddi, 1997 .

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

K. Vaddi, M. Luchi, 2012, Expert opinion on investigational drugs.

Selective Inhibition of Eosinophil Influx into the Lung by Small Molecule CCR3 Antagonists in Mouse Models of Allergic Inflammation

K. McIntyre, S. Mandlekar, J. Trzăskos, 2006 .

Regulation of monocyte integrin expression by beta-family chemokines.

K. Vaddi, R. Newton, 1994, Journal of immunology.

C5aR – C5 anaphylatoxin receptor

K. Vaddi, 1997 .

Comparison of biological responses of human monocytes and THP‐1 cells to chemokines of the intercrine‐β family

K. Vaddi, R. Newton, 1994, Journal of leukocyte biology.

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors

J. Luengo, K. Vaddi, Rupa Shetty, 2019, ACS medicinal chemistry letters.

Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.

P. Scherle, K. Vaddi, Joseph Glenn, 2010, ACS medicinal chemistry letters.

IL-8RB – Interleukin 8 receptor, type B

K. Vaddi, 1997 .

SDF-1 – Stromal cell derived factor-1

K. Vaddi, 1997 .

MGSA – Melanoma growth stimulatory activity

K. Vaddi, 1997 .

IL-8RA – Interleukin 8 receptor, type A

K. Vaddi, 1997 .

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Abstract #2848: Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia

J. Fridman, X. Wen, T. Burn, 2009 .

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

S. Verstovsek, J. Fridman, P. Scherle, 2007 .

IL-8 – Interleukin-8

K. Vaddi, 1997 .

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

P. Scherle, K. Vaddi, M. Covington, 2010, Bioorganic & medicinal chemistry letters.

α,β-Cyclic-β-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-α converting enzyme (TACE)

David D. Christ, K. Vaddi, M. Covington, 2008 .

Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.

Zelda R Wasserman, J. Trzăskos, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.

J. Trzăskos, K. Vaddi, M. Covington, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.

Xiaohua He, John Roderick, J. Trzăskos, 2004, Bioorganic & medicinal chemistry letters.

Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.

J. Trzăskos, K. Vaddi, M. Covington, 2008, Bioorganic & medicinal chemistry letters.

A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.

J. Trzăskos, Xiao-tao Chen, K. Vaddi, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

J. Trzăskos, T. Maduskuie, B. W. King, 2004 .

PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.

R. Garzon, G. Behbehani, R. Baiocchi, 2020, JCI insight.

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.

D. J. Rogier, P. Scherle, R. Devraj, 2011, Bioorganic & medicinal chemistry letters.

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

Lixin Shao, Michael Xia, D. J. Rogier, 2011, ACS medicinal chemistry letters.

CCR2 modulates inflammatory and metabolic effects of high-fat feeding.

R. Leibel, I. Charo, S. Weisberg, 2006, The Journal of clinical investigation.

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, T. Burn, 2005, The Journal of Immunology.

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

J. Minna, L. Girard, M. Peyton, 2006, Cancer cell.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

P. Tassone, J. Fridman, D. Chauhan, 2009, Molecular Cancer Therapeutics.

Increased monocyte MCP-1 production in acute alcoholic hepatitis.

C. McClain, S. Barve, D. Hill, 1999, Cytokine.

The Role of the JAK/STAT Signalling Pathway in Immunoregulation of Gastrointestinal Cancers

K. Vaddi, 2017 .

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

3 – Chemokines: an overview

K. Vaddi, 1997 .

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

J. Fridman, Jun Li, X. Wen, 2010, Neoplasia.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

O. Abdel-Wahab, R. Levine, J. Bromberg, 2010, Blood.

INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies

Jun Yu Li, Qianqian Wang, B. Rumberger, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

H. Kantarjian, S. Verstovsek, A. Tefferi, 2008 .

Human Plasma In‐Cell Western Assays—An In vitro Predictor for In vivo Pharmacology in Oncology Drug Discovery

P. Scherle, D. Rominger, K. Vaddi, 2021, Current protocols.

MCP-1 – Monocyte chemoattractant protein-1

K. Vaddi, 1997 .

TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS

K. Vaddi, 2007 .

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma

K. Shilo, R. Baiocchi, L. Alinari, 2021, PloS one.

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation

J. Byrd, S. Pileri, S. Chen‐Kiang, 2023, Nature Communications.

Modulation of macrophage activation by ammonium metavanadate.

C. Wei, K. Vaddi, 1996, Journal of toxicology and environmental health.

Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL

H. Koblish, P. Scherle, T. Maduskuie, 2015 .

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

J. Fridman, P. Scherle, K. Vaddi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.

J. Fridman, P. Scherle, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2008 .

Severe retinal degeneration associated with disruption of semaphorin 4A.

D. Rice, A. Sands, G. Hansen, 2004, Investigative ophthalmology & visual science.

Biology of TACE inhibition

K. Vaddi, M. Covington, P. Haley, 2001, Annals of the rheumatic diseases.

Abstract 983: Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1

N. Bhagwat, P. Scherle, K. Vaddi, 2021, Experimental and Molecular Therapeutics.

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

J. Grandis, J. Fridman, Bin-Bing S. Zhou, 2007, Clinical Cancer Research.

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013 .

Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.

R. Magolda, J. Trzăskos, K. Vaddi, 2004, Bioorganic & medicinal chemistry letters.

MCP-2 – Monocyte chemoattractant protein-2

K. Vaddi, 1997 .

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

M. Cazzola, T. Barbui, H. Kantarjian, 2010 .

Effect of ammonium metavanadate on the mouse peritoneal macrophage lysosomal enzymes.

C. Wei, K. Vaddi, 1991, Journal of toxicology and environmental health.

PAFR – Platelet activating factor receptor

K. Vaddi, 1997 .

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader

N. Bhagwat, P. Scherle, P. Pitis, 2022, Cancer Research.

ENA-78 – Epithelial derived neutrophil attractant-78

K. Vaddi, 1997 .

BLR-1/MDR-15 – Burkitt's lymphoma receptor-1/ Monocyte-derived receptor-15

K. Vaddi, 1997 .

Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.

J. Fridman, P. Scherle, K. Vaddi, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.

M. Bower, R. Wynn, J. Fridman, 2007, Journal of medicinal chemistry.

Abstract 3523: Discovery of a novel BET inhibitor INCB054329

R. Wynn, X. Liu, Jun Li, 2015 .

Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways

D. Butler, Cem Meydan, R. Baiocchi, 2022, Blood.

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

J. Byrd, S. Chen‐Kiang, R. Baiocchi, 2019, Blood.

DARC – Duffy antigen/chemokine receptor

K. Vaddi, 1997 .

EMF-1 – Embryo fibroblast protein-1

K. Vaddi, 1997 .

The Leucocyte Antigen Factsbook

M. Horton, C. Isacke, A. Barclay, 1993 .

MCP-3 – Monocyte chemoattractant protein-3

K. Vaddi, 1997 .

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2010, The New England journal of medicine.

Characterization of a Novel Rodent-Active Discovery and Pharmacological

P. Scherle, F. Baribaud, L. Leffet, 2013 .

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

S. Verstovsek, K. Vaddi, N. Sarlis, 2014, International journal of general medicine.

R. Wynn, P. Scherle, K. Vaddi, 2022, Bioorganic & medicinal chemistry letters.

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

K. Vaddi, M. Luchi, 2012, Expert opinion on investigational drugs.

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

J. Fridman, H. Koblish, P. Scherle, 2010, Molecular Cancer Therapeutics.

FPR – N-formyl peptide receptor

K. Vaddi, 1997 .

Ruxolitinib: a targeted treatment option for patients with polycythemia vera Blood and Lymphatic Cancer: Targets and Therapy

S. Verstovsek, K. Vaddi, J. Kiladjian, 2016 .

INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies

Jun Yu Li, Qianqian Wang, B. Rumberger, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.

J. Fridman, P. Scherle, K. Vaddi, 2006, Cancer Biology & Therapy.

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

P. Scherle, K. Vaddi, M. Covington, 2010, Bioorganic & medicinal chemistry letters.